Genuone Sciences will support the entireprocess from production to supply and distribution of these products.
In addition to the existing method ofdistributing domestically produced products to Vietnam, the Korean company cannow produce and supply products directly in the Southeast Asian country.
Samsoo Lee, CEO of Genuone Sciences Inc,described the strategic cooperation with Imexpharm as an important one thathelps Genuone gradually access the Vietnamese pharmaceutical market, apotential and dynamic market in the Southeast Asia region.
To date, Imexpharm owns four manufacturingclusters, including three EU-GMP manufacturing clusters with eleven productionlines that meet EU-GMP standards. This has made Imexpharm the largestpharmaceutical manufacturing company with EU-GMP manufacturing clusters and thehighest number of EU-GMP production lines. /.